Comprehensive pancancer analysis reveals that LPCAT1 is a novel predictive biomarker for prognosis and immunotherapy response
Authors:
- 4 August 2024
- journal article
- research article
- Published by Springer Nature in Apoptosis
- Vol. 29 (11-12) , 2128-2146
Abstract
Lysophosphatidylcholine acyltransferase 1 (LPCAT1) is a crucial enzyme involved in phospholipid metabolism and is essential for maintaining the structure and functionality of biofilms. However, a comprehensive examination of the role of LPCAT1 across various cancer types is lacking. Multiple public databases have been utilized to examine LPCAT1 expression, genetic alterations, methylation, prognosis, biological function, and its relationship with antitumor immunity in different cancer types. The function of LPCAT1 in glioma, breast cancer and liver cancer cells was further verified using in vitro experiments. Our research indicated that LPCAT1 is upregulated in various cancers and is accompanied by a wide range of amplification mutations. Higher LPCAT1 expression was associated with poorer prognosis across multiple cancers. Further in vitro experiments demonstrated that interfering with LPCAT1 expression increased apoptosis in glioma, breast cancer and liver cancer cells and concurrently suppressed their proliferation and migration. Functional enrichment analysis revealed that LPCAT1-associated genes were primarily enriched in immune and cancer progression pathways, such as the JAK/STAT, MYC, and EMT, etc. Moreover, LPCAT1 expression was closely associated with immune cell infiltration and immune checkpoint-related gene expression. Interestingly, LPCAT1 expression levels were generally higher in patients in the immunotherapy response group. The combination of LPCAT1 and PDL1 serves as an effective predictor of immunotherapy response. In conclusion, LPCAT1 is involved in immune regulation and tumor progression and holds promise as a biomarker for predicting patient outcomes and immunotherapy efficacy.Keywords
Funding Information
- The Innovation Platform and Talent Plan of Hunan Province (2023SK4019)
- Beijing Life Oasis Public Service Center (cphcf-2023-037)
This publication has 64 references indexed in Scilit:
- The roles of ferroptosis in cancer: Tumor suppression, tumor microenvironment, and therapeutic interventionsCancer Cell, 2024
- Advances in cancer immunotherapiesCell, 2023
- Sangerbox: A comprehensive, interaction‐friendly clinical bioinformatics analysis platformiMeta, 2022
- Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trialCancer Cell, 2021
- Cathepsin C promotes breast cancer lung metastasis by modulating neutrophil infiltration and neutrophil extracellular trap formationCancer Cell, 2021
- A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder CancerCell, 2020
- A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient SamplesCell, 2018
- Universal Patterns of Selection in Cancer and Somatic TissuesCell, 2017
- Gene Body Methylation Can Alter Gene Expression and Is a Therapeutic Target in CancerCancer Cell, 2014
- Lysophosphatidylcholine acyltransferase 1 (LPCAT1) overexpression in human colorectal cancerJournal of Molecular Medicine, 2008